ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Accrual of Alzheimer's disease pathology as a function of proximity to parental dementia onset.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Accrual of Alzheimer's disease pathology as a function of proximity to parental dementia onset.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhether temporal proximity to parental onset of dementia (PPO) can be used to estimate timing of the preclinical stage of sporadic Alzheimer's disease (AD) remains uncertain.
methodsWe investigated cross-sectionally adults aged > 50 without dementia included in the European Prevention of Alzheimer's Dementia (EPAD) study. PPO was tested as a predictor of quantitative levels of cerebrospinal fluid (CSF) β-amyloid (1-42) (Aβ1-42) in those with a parental history of dementia (
resultsShorter PPO predicted lower CSF Aβ1-42 level (β = 9.357; T = 4.161; DISCUSSION: PPO may provide a valid method of stratifying risk of early AD pathologic change in APOE-𝜀4 carriers, with empirical and clinical applications. Highlights: Proximity to age of parental dementia onset can predict amyloid accrualThe effect is APOE-𝜀4 dose-dependent and APOE-𝜀2 appears to provide protectionPPO does not appear to predict further advancement along the AD continuumIn the era of anti-amyloid treatments, this may inform timing of amyloid screeningUsed as an empirical metric, PPO could help elucidate the natural history of LOAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.